Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study
Digestive Diseases and Sciences · 2025
DOI: 10.1007/s10620-024-08764-4 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Digestive Diseases and Sciences, 2025. Verfasst von Basile Njei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Digestive Diseases, Yale University School of Medicine/VA Connecticut Healthcare System, New Haven, CT, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Cardiovascular Diseases, Fatty Liver. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NIH HHS.
Abstract (Originalsprache)
BACKGROUND AND AIMS: for Asians) vs. non-lean individuals with MASLD have reported mixed results. We aimed to compare incident clinical outcomes and mortality between lean and non-lean individuals with compensated MASLD cirrhosis in a large national cohort. METHODS: This was a retrospective cohort study of patients with newly diagnosed compensated MASLD cirrhosis in the Veterans Health Administration between 01/2008 and 05/2021. The primary outcome was incident hepatic decompensation, and secondary outcomes were incident major adverse cardiovascular events (MACE) and all-cause mortality. Multivariable Cox proportional hazard models were used to assess association. Fine and Gray competing risk regression was used where applicable. RESULTS: The study included 15155 patients with MASLD cirrhosis: 1,597 lean and 13558 non-lean patients. Included patients were mostly male (95%), median age was 67 years, and 72.8% were non-Hispanic white. At baseline, the prevalence of diabetes was lower in lean vs. non-lean individuals (46.7 vs. 73.9%, p < 0.001). In multivariable models, lean status was associated with a 64% increased risk of all-cause mortality (aHR = 1.64) but decreased risk of hepatic decompensation (aSHR = 0.67). Lean individuals experienced significantly higher rates of cardiovascular-related mortality (aHR = 1.40). CONCLUSION: Lean MASLD patients with compensated cirrhosis had a higher mortality risk but a lower risk of hepatic decompensation than non-lean patients. Despite having a better baseline cardiometabolic profile and similar rates of MACE, lean individuals with MASLD cirrhosis have a higher risk of cardiovascular mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Digestive Diseases, Yale University School of Medicine/VA Connecticut Healthcare System, New Haven, CT, USA.
- University of Miami and Miami VA Health System, Miami, FL, USA.
- University of Pennsylvania, Philadelphia, PA, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Hospital of the University of Pennsylvania, Philadelphia, PA, USA. nadim.mahmud@pennmedicine.upenn.edu.
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- NIH HHS
- Yale Liver Center
- NIH CTSA
- NIH
Zitieren
APA
Njei, B., Mezzacappa, C., John, B. V., Serper, M., Kaplan, D. E., Taddei, T. H., & Mahmud, N. (2025). Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08764-4
Vancouver
Njei B, Mezzacappa C, John BV, Serper M, Kaplan DE, Taddei TH, et al. Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study. Digestive Diseases and Sciences. 2025. doi:10.1007/s10620-024-08764-4
BibTeX
@article{Njei2025,
author = {Njei, Basile and Mezzacappa, Catherine and John, Binu V and Serper, Marina and Kaplan, David E and Taddei, Tamar H and Mahmud, Nadim},
title = {Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study},
journal = {Digestive Diseases and Sciences},
year = {2025},
doi = {10.1007/s10620-024-08764-4}
}
EUVIMED